Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell 4Lymphoma, Follicular 3Lymphoma 3Lymphoma, Mantle-Cell 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 62Rituximab 47fludarabine 35fludarabine phosphate 27obinutuzumab 17Mycophenolic Acid 16ibrutinib 15Whole-Body Irradiation 15Lenalidomide 15Specimen Handling 14Prednisone 14Etoposide 14venetoclax 13pirtobrutinib 13Doxorubicin 13pembrolizumab 12Tacrolimus 12Magnetic Resonance Spectroscopy 11Granulocyte Colony-Stimulating Factor 11Filgrastim 11Biopsy 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10X-Rays 9Bendamustine Hydrochloride 9polatuzumab vedotin 8glofitamab 8acalabrutinib 8Immunotherapy, Adoptive 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × loncastuximab tesirine × 1 year × Clear all
NCT05053659 2026-02-12

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡